The role of heat shock proteins in antigen cross presentation

Ayesha Murshid1, Jianlin Gong2 and Stuart K. Calderwood1*

1 Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
2 Boston University Medical Center, Boston, MA, USA

INTRODUCTION

Heat shock proteins (HSPs) are a class of polypeptides powerfully induced by heat shock that mediate profound levels of stress resistance (Craig, 1985; Ellis, 2007). HSPs are molecular chaperones, binding to (holding) and refolding other cellular polypeptides (clients) with aberrant conformations (Ellis, 2007). There are a number of families of molecular chaperone families (a–d), with members of class a (Hsp70, Hsp110, GRP170) and class c (Hsp90, Grp94/Gp96) thought to be of particular significance in tumor immunology (Murshid et al., 2011c). (Grp is the abbreviation for glucose regulated protein and such proteins are retained in the endoplasmic reticulum, ER.) The molecular chaperone activity of class a and class c chaperones appears to be conferred by two functional domains: a dedicated peptide binding domain that seizes client polypeptides and an ATPase domain (Scheibl et al., 1998; Mayer and Bukau, 2005; Vogel et al., 2006). HSPs are allosteric molecules, one domain reciprocally affecting the other, and when polypeptide moieties bind to the peptide binding domain, ATP is hydrolyzed to ADP and orthophosphate and when ATP binds, associated peptides are discarded. These properties have been intensely studied for Hsp70 and Hsp90 and are largely inferred for the sibling proteins. The ability to hold polypeptide clients appears to correlate with the size of class a chaperones, the smaller class a member (Hsp70) binding to smaller peptides with medium affinity while larger class a chaperones (Hsp110 and Grp170), with very large peptide binding domains, bind tightly to their clients, including peptides and whole proteins (Oh et al., 1999; Park et al., 2006).

Heat shock protein–peptide complexes (HSP-PC) can be used as vaccines to elicit antigen-specific cytotoxic lymphocytes (CTL) responses (Srivastava, 2000; Manjili et al., 2002; Wang et al., 2003; Enomoto et al., 2006; Gong et al., 2010). In order for polypeptides bound to HSPs to activate adaptive immunity, associated antigens must be internalized by antigen presenting cells (APC) and inserted into the antigen presentation pathways. Indeed, HSPs have been shown to be taken up by dendritic cells (DC), the most efficient professional APC (Steinman et al., 1983; Heath and Carbone, 2009). Antigen presentation occurs through a number of pathways. Intracellular proteins were shown to be processed by digestion through the multiple protease activities in the proteasome and antigens presented on the cell surface by major histocompatibility class I (MHC-I) molecules found in all cells and thus displayed to CD8+ T cells to permit immunosurveillance (Neefjes and Momburg, 1993). By contrast, exogenous antigens after internalization into immune cells are processed in lysosomes and presented on the cell surface by major histocompatibility class II (MHC-II) molecules restricted to cells of the immune system (Cresswell, 1994). It was subsequently shown that another antigen presentation pathway exists permitting external antigens to enter the MHC class I pathway (Norbury et al., 2002, 2004). This process, antigen cross presentation permits external antigens to be presented by APC in the context of MHC class I and activate CD8+ CTL to kill virus infected or malignant cells (Norbury et al., 2002, 2004; Figure 1). Antigen cross presentation was shown to be a complex process requiring external antigens to enter cells, penetrate sites for protein processing, and associate with MHC class I molecules in intracellular vesicular structures although many aspects of this process are incompletely understood. We aim to elucidate some of the mechanisms by which antigens bound to HSP interact with APC and mediate antigen presentation.
FIGURE 1 | Antigen presentation pathways for HSP-bound polypeptides. HSP/PCs bind to surface receptors on DC including SRECI and LOX-1 and are internalized in complexes with the receptors. Binding to these receptors may also trigger secondary activation of Toll-like receptors (TLR2 or TLR4) that may amplify antigen cross presentation. Alternatively some studies suggest direct binding of HSPs to TLR. HSP binding to cell surface SRA/CD204 is inhibitory to TLR4 activity and likely antagonizes the immune responses induced by HSPs through LOX-1 or SRECI. HSP/PC are internalized by SRECI or LOX-1 into endosomes with the subsequent release of the peptides from the HSP/PC complex. Such peptides are then processed either within endosomes or undergo trafficking to the cytosol where they encounter the proteasomal system. Processed peptides are then loaded either onto MHC class I in the ER or phagosomes or onto MHC class II molecules in lysosomes and presented to, respectively CD8+ T cells and CD4+ T cells. The triage mechanisms directing HSP-chaperoned peptides toward either of these two pathways are currently not known.
and tumorigenesis appears to be maintained by driver mutations in minority clones of tumor-initiating cells (TIC; Carter et al., 2009; Hanahan and Weinberg, 2011). Thus many of the random mutations accumulating in the large non-TIC population may have passenger status and are unlikely to select for malignancy. A high proportion of the antigenic epitopes in individual cancers could therefore be unique and not shared with other tumors. However, many tumors express common antigens (such as HER2-neu and MUC1 in breast cancer) or re-express embryonic and developmental genes such as Mart1 and gp100 common to many cancers (Engelhard et al., 2002). For tumor immunotherapy in patients, Grp94 and Hsp70 vaccines have been used in an autologous mode, with the patients receiving HSP complexes derived from their own primary tumors for immunotherapy (Srivastava and Old, 1988). This approach was based on experimental studies of chemically induced rodent cancers, in which Grp74 and Hsp70 vaccines were shown to be effective only in an autologous context and were not cross reactive even with tumors from matched animals bearing tumors induced by the same carcinogen (Udono and Srivastava, 1993; Chandawarkar et al., 2004).

Characterizing the antigenic peptide repertoires associated with individual HSPs extracted from tumor cells has however rarely been attempted. Thus although it is suspected that the individual class a and class c HSPs chaperone a wide spectrum of potential antigenic epitopes that may be representative of the cell proteome and that individual HSPs may favor distinct subpopulations of such peptides, these issues have not been comprehensively studied and the question remains open.

**PATHWAYS OF ANTIGEN CROSS PRESENTATION: SOLUBLE, PARTICULATE, AND HSP–CHAPERONED ANTIGENS**

Antigen presenting cells utilize at least two pathways for sampling external antigens and displaying them to T lymphocytes. These are the MHC class I and MHC class II pathways. However, the mechanisms used for sorting and trafficking of antigens between the MHC class I or class II pathways varies according to the physical nature of the antigen (Inaba and Inaba, 2005). Particulate and soluble antigens are dealt with quite differently.

(a) **Particulate antigens** are taken up by phagocytosis and enter vesicular structures known as phagosomes (Ackerman et al., 2003; Cresswell et al., 2005; Inaba and Inaba, 2005). Triage of antigens between the Class I and Class II pathways then appears to involve close regulation of the intraphagosomal pH. The previously acidic pH of the phagosome is initially increased, favoring antigen processing through the Class I pathway. After some minutes, these phagosomes are re-acidified, permitting antigen processing toward the Class II pathway (Inaba and Inaba, 2005).

Following triage between MHC class I and class II pathways, the cross presentation of particulate antigens involves itself at least two variant mechanisms. In the Cytosolic Pathway of Antigen Cross Presentation, antigens are taken up into phagosomes and, after partial processing in these organelles, exported into the cytoplasm where they are hydrolyzed into short peptides within the proteasome. The processed peptides are then re-imported into the ER by transporter associated with antigen presentation (TAP), enter the conventional antigen presentation pathway, and become loaded onto appropriate MHC class I molecules (Rock and Shen, 2005). A variation on this mechanism has been proposed in which the antigen processing machinery of the ER becomes associated with phagosomes and loading onto MHC class I occurs in these organelles (Rock et al., 2005).

A second, alternative pathway for cross presentation of particulate antigens involves the **Vacuolar Pathway**, also known as the TAP-independent pathway of cross presentation (Rock and Shen, 2005; Ackerman et al., 2006). This route of antigen presentation is rapid compared to the cytosolic/proteasome pathway and obviates the need for polypeptides to be pumped in and out of the cytoplasm. In this case, antigens are taken up into endosomes and directly processed by endogenous proteases such as the cysteine protease cathepsin S, loaded onto MHC class I molecules recycling from the cell surface and then trafficked back to the surface in recycling endosomes.

(b) **Soluble antigens** appear to be taken up by APC and partitioned toward the MHC class I and MHC class II pathways by different mechanisms compared to particulate antigens. Sorting to the class I and class II routes occurs at the cell surface through either non-specific macrophagocytosis or endocytosis, involving surface receptors. Uptake of antigens directed to the antigen cross presentation pathways may involve Fc receptors, and c-type lectins including CLEC9A, DC-SIGN, DEC205, and the mannose receptor 1 (Bonifaz et al., 2002; Burgdorf et al., 2006, 2010; Idoyaga et al., 2011; Tacken et al., 2011). C-type lectins have in common the possession of a recognition domain that determines their carbohydrate specificity and have been studied mostly in regard to interaction with pathogens (Geijtenbeek and Gringhuis, 2009). Cross presentation of internalized antigens next involves the two variant pathways described above for particulate antigens after antigen–receptor complexes are internalized into endosomes.

**EXTRACELLULAR HSP–PEPTIDE COMPLEXES AND ANTIGEN CROSS PRESENTATION**

The uptake of HSP.PC may involve receptors expressed on the surface of DC and can precede antigen presentation through the Class I and Class II pathways (Jeannin et al., 2005; Theriault et al., 2006; Kurotaki et al., 2007; Murshid et al., 2011b). The receptors involved in this process appear to differ from those that mediate uptake of soluble, unchaperoned antigens, and the c-type lectins involved in the latter process do not seem to be major endocytic receptors for HSP.PC in APC (Theriault et al., 2006). Instead HSPs bind mainly to scavenger receptors (SR) such as SRECI/Scarf1, FEEL-1/Stabilin-1, LOX-1, SRA/CD204, and LRP1/CD91 (Binder et al., 2000; Delnette et al., 2002; Theriault et al., 2006; Murshid et al., 2011b; Figure 1). SR were first characterized in studies of uptake of chemically modified low-density lipoproteins (LDL) by endothelial cells and appear to bind a wide variety of other molecules, including HSPs (Murshid et al., 2011b). However, Hsp70 can be bound by some molecules with c-type lectin specificity, including the natural killer (NK) cell receptor NKG2D; LOX-1 belongs to both SR and c-type lectin families (Theriault et al., 2006; Murshid et al., 2011b).
et al., 2011a). As FEEL-1 is not abundantly expressed in DC we have not further pursued its potential role in HSP-mediated antigen cross presentation (Chu, B., Murshid, A., and Calderwood, S. K., unpublished). The status of LRPR/CD91 in HSP binding and cross presentation is somewhat controversial. This protein has been proposed as a common HSP receptor (Binder et al., 2000; Srivastava, 2002). However, LRPR/CD91 is not abundantly expressed in most DC subtypes and binding of Grp94, calreticulin, and Hsp70 to the receptor was not detected in a number of studies (Delneste et al., 2002). Nonetheless, LRPR/CD91 is not abundantly expressed in DC and receptor binding of Grp94, Hsp110, and Grp170 with or without associated antigens (Berwin et al., 2004; Murshid et al., 2010). Hsp90–Ova peptide exposure was reduced by exposure to chloroquine, an inhibitor of vesicular acidification suggesting that low pH may be required at least for cross presentation through the vesicular pathway (Murshid et al., 2010). So far it has been established that both the endosome–plasma membrane and endosome to cytosol–cell membrane mechanisms are involved in HSP70 and Hsp90-mediated antigen cross presentation in BMDC (Murshid et al., 2010). Partition of antigens between these two pathways may depend on the size of the client polypeptide associated with the HSP. Smaller, Ova-derived peptides bound to Hsp90 could be efficiently cross presented through a mechanism resembling the vesicular pathway and such processing was blocked by cysteine protease inhibitors and, primaquine an antagonist of membrane recycling (Murshid et al., 2010). Larger polypeptides associated with Hsp90, such as full length ovalbumin required TAP expression and proteasome function, indicating a key role for the endosome–cytosol pathway in processing these larger antigens (Murshid et al., 2010). HSP chaperoning of peptide antigens may increase the efficiency of antigen processing by protecting peptides from proteolysis during trafficking through the cell compartments and reducing the amounts of antigen required to initiate CD8+ T cell cross priming (Kunisawa and Shastri, 2006). One question that is currently unclear is how far along the journey of antigen cross presentation the HSP-receptor–polypeptide complex remains intact. Hsp90, SRECI, and Ova-derived peptides have been detected co-localizing in endosomal compartments of BMDC (Murshid et al., 2010). In addition, in DC incubated with Hsp90–Ova complexes, internalized Hsp90 and Ova were shown to co-localize with cytosolic proteasomes (Oura et al., 2011). Localization of Ova to proteasomes and TAP-dependent antigen cross presentation could be abolished by introduction of anti-Hsp90 antibodies into cells, indicating a key role for Hsp90 in targeting associated Ova molecules to proteasomes (Oura et al., 2011). It has been shown recently that intracellular Hsp90 plays an essential role in antigen cross presentation by permitting the transport of model antigen Ova out of endosomes and into the cytosol to permit processing by the proteasome (Ichiyagawt, 2010;
Imai et al., 2011). By contrast with free Ova, cross presentation of Hsp90–chaperoned Ova appeared to be independent of endogenous Hsp90, suggesting that exogenous Hsp90 may facilitate antigen transport across the endosomal membrane independently of the endogenous chaperone (Oura et al., 2011). Ultimately, peptides dissociate from the HSP prior to processing and presentation and receptors such as SREC1 are likely recycled to the cell surface. Fluorescently labeled Hsp90 was observed for approximately 60 min in murine BMDC, after binding and internalization, before fluorescence became undetectable (Murshid, A., unpublished data). Hsp90 taken up from the extracellular medium and entering endosomes may be broken down by intravesicular proteases or lysosomal hydrolases.

ROLE OF INTRACELLULAR MOLECULAR CHAPERONES IN CROSS PRESENTATION OF ANTIGENS IN CELLULAR MATERIALS ENGULFED BY APC

Tumor cells or virally infected cells may trigger immunity either directly when MHC class I antigen complexes on the surface interact with CD8+ T cells or when such cells die, are engulfed by APC and epitopes are cross presented to the CD8+ cells (Wolkers et al., 2001). There has been some suggestion that HSPs might play a role in the second process, in cross presentation of antigens sequestered by molecular chaperones by APC after engulfment of cell bodies. HSP-chaperoned peptides appear to exist in detectable quantities in cells and could be significant in this latter process. Indeed it was suggested by Binder et al. (2000) that essentially all antigenic epitopes in cells may be bound to molecular chaperones (Binder and Srivastava, 2005). However in a study of Ova epitope presentation in cell lysates, free unprocessed proteins appeared to be the dominant form of antigens for cross priming, far exceeding the activities of free or HSP-chaperoned peptides (Shen and Rock, 2004). Most peptides generated by proteolysis of cytoplasmic proteins have a very short half-life, surviving for only a few seconds, although a minority can survive for longer periods by association with TAP (Reits et al., 2003). There has been some suggestion that HSPs could chaperone such peptides in the cytoplasm and protect them from cytoplasmic aminopeptidases (Srivastava, 2002). Intracellular chaperones may acquire peptide antigens during endogenous antigen processing (Kunisawa and Shastri, 2003, 2006). Indeed Shastri et al. have shown that Hsp90a is essential in stabilizing large peptide intermediates generated by the proteasome from Ova and for presentation through the MHC class I pathway (Kunisawa and Shastri, 2006). In addition, a minority of viral epitopes that can bind Hsp90α appear to be stabilized, and are important in cross priming (Lev et al., 2008). However the exact place of HSPs in cytoplasmic antigen processing is uncertain. When peptides are taken up by TAP into the ER they could potentially encounter other molecular chaperones, including the Hsp70 paralog Grp78 and the Hsp90 paralog Grp94, molecules with suspected immune functions. It is not clear whether Grp78 binds peptides or participates in antigen presentation although it has known immune functions in the chaperoning of IgG (Kozutsumi et al., 1989). In addition, Grp94 does not appear to participate in cross priming of anti-viral CD8+ cells in vivo (Nischitta, 2003; Lev et al., 2009). Another ER chaperone shown in vitro to bind avidly to polypeptide clients is Grp170 (Park et al., 2006). However it is not clear whether ER resident Grp170 can acquire peptide antigens in vivo or can play a role in antigen presentation, although its high avidity for peptides and proteins suggests investigation of such a possibility.

RELEASE OF HSPs FROM CELLS INTO THE EXTRACELLULAR ENVIRONMENT

Heat shock proteins can also be released from cells, tissues, and access the extracellular environment, although their functions outside the cell are largely unknown and much debated (Pockley et al., 2008). HSPs can be released from tumor cells or macrophages into the extracellular microenvironment through mechanisms involving secretory lysosomes, very similar to the processes used by cells to release interleukin-1β (Mambula and Calderwood, 2006b). This pathway of non-canonical HSP secretion occurs at a gradual basal rate and can be triggered in cells by stresses such as fever range heat or by exposing macrophages to live E. coli bacteria (Mambula and Calderwood, 2006b; Mambula, S. S., Murshid, A., and Calderwood, S. K., in preparation). HSPs released in this way could potentially export antigenic peptides acquired during intracellular antigen processing as cargo, interact with APC and trigger cross priming of CD8+ subsets. However, it is not clear how stable antigen binding would be under these circumstances. It is known that for hspA family chaperones such as Hsp70, peptide binding is relatively stable when ADP rather than ATP is bound to the chaperone. Hsp70 is also released from necrotic cells and under these circumstances might be thought to bind associated polypeptides, as intracellular ATP levels would decline rapidly in necrosis and the chaperone, in its ADP-bound form would bind peptides more effectively (Mambula and Calderwood, 2006a). Hsp70 released from cells undergoing necrotic death has been shown to lead to a strong T cell mediated anti-tumor immune response (Daniels et al., 2004). In addition, it was shown that Grp170, engineered for secretion into the extracellular environment initiated tumor rejection due to activation of NK and CD8+ cells, indicating the potential of this approach (Wang et al., 2003).

In addition to secretion in free form, HSPs have been shown to be released from cells after being packaged in exosomes. Exosomes derived from multivesicular bodies in DC contain Hsp70 and are known to play a major role in cross priming of T lymphocytes (Chaput et al., 2006). Thus Hsp70 in exosomes could potentially play a significant role in immunity. However, exosomes from tumors (EL4 Thymoma) which contain Hsp70 on the vesicular surface were shown to be immunosuppressive through interaction with myeloid derived suppressor cells (MDSC; Chalmin et al., 2010). Relatively little work has been carried out in this interesting area and we anticipate further studies.

EXTRACELLULAR HSPs AND THE CLASS II PATHWAY

Cross presentation of HSP-associated antigens, although essential, would not be sufficient to fully program CTL and in the absence of other signals, CTL would ultimately fail to actively proliferate and could undergo programmed cell death. For a sturdy CTL response, DC would process and present antigens via the MHC class II pathway and thus activate CD4+ T helper cells. It has
been shown that HSPs can chaperone external antigens through the MHC class II pathway and activate CD4+ T cells (Gong et al., 2009). As mentioned above, unchaperoned antigens, after uptake into phagosomes, traverse separate trafficking routes in DC that direct them to compartments in which association with MHC class I or II molecules can occur. It is not clear which mechanisms are involved in the partitioning of HSP-chaperoned antigens into these pathways. We have shown however that SRECI is involved in HSP-mediated CD4+ T cell activation and our preliminary studies indicate that the early endocytic and regulatory stages of this process, such as uptake of HSP/PC through SRECI, involve similar pathways to those in Class I presentation (Gong et al., 2009; Murshid, A., and Calderwood, S. K., in preparation). Activation of CTL is thought to require DC licensing, in which an individual DC interacts with both CD4+ and CD8+ T cells (Bennett et al., 1997, 1998). Initial interaction of CD40 ligand on the CD4+ T cell surface with CD40 on the DC sets in motion a series of events including the induction of co-stimulatory molecules such as CD80 (B7-1), CD86 (B7-2) that permit subsequent CD8+ T cells activity (Kurts et al., 2010; Figure 1). Co-stimulatory molecules are recognized by counter receptors such as CD28 expressed on T cells and reinforce the signals induced in CD8+ T cells by MHC–peptide complex–T cell receptor binding (van der Merwe et al., 1997; Rudd et al., 2009; Figure 1). Most HSPs are likely to bind to a wide spectrum of intracellular antigens, containing both MHC class I and class II epitopes and may favor the reactions involved in DC licensing.

HSP ASSOCIATION WITH PATTERN RECOGNITION RECEPTORS

Cytotoxic lymphocytes activation can also be reinforced by signals induced by pathogen-associated molecular patterns (PAMPs). During infection, PAMPs bind to several classes of pattern recognition receptors (PRR) such as Toll-like receptors (TLR) and trigger innate immune responses in APC (Yamamoto and Takeda, 2010). This type of signaling activates a number of transcription factors, most notably nuclear factor-κB (NFκB) that can stimulate transcription of genes encoding inflammatory cytokines and co-stimulatory molecules such as B7-1 and B7-2 (Parra et al., 1995; Rudd et al., 2009). Innate immune activation through these pathways can thus reinforce CTL programming through pathways overlapping those induced by CD40L–CD40 interactions between CD4+ T cells and DC (Maurer et al., 2002; Schulz et al., 2005; Najar and Dutz, 2007; Figure 1). HSPs may potentially function as DAMPs (damage associated molecular patterns) and induce innate immunity under sterile conditions through interaction with PRR (Chase et al., 2007; Wheeler et al., 2009). Indeed, there is an evidence for HSPs interacting with PRR such as TLR2 and TLR4 (Gong et al., 2009; Figure 1). It was shown that SRECI-dependent tumor immunity induced by Hsp70 vaccines requires TLR signaling and knockout of the TLR signaling intermediate Myd88 or the receptors TLR2 and TLR4 obliterates tumor immunity (Gong et al., 2009). In addition to affecting innate immune transcription, TLR signaling also mediates a number of stages in antigen cross presentation and positive HSP interaction with TLRs may thus reinforce antigen cross presentation (Amigorena and Savina, 2010). As CTL programming involves the interaction of three rare cell types, including DC, CD8+ T cells, and CD4+ T cells, this confluence may be strongly influenced by the release of inflammatory CCL cytokines from DC. It may be notable that Hsp70 has been shown to trigger release of CCL cytokines in a TLR4 dependent manner and that mycobacterial Hsp70 binds directly to CCL receptor CCR5 (Whittall et al., 2006; Chen et al., 2009).

HSP–SCAVENGER RECEPTOR INTERACTIONS AND TRANSMEMBRANE SIGNALING

In addition to internalizing bound peptides, ligand-bound HSPs may play significant roles in cell signaling pathways that impact immunity. LOX-1 and SRECI can both interact with TLR2 to induce innate immune signaling and transcription (Jennin et al., 2005). Although little is known regarding HSP–LOX-1 signaling, binding of LOX-1 to other ligands, such as modified LDL induces MAP kinase activity, NF-κB, and pro-inflammatory signaling through the small intracellular domain of the receptor (Chen et al., 2002). However, when HSPs interact with class I scavenger receptor SRA/CD204, innate immune signaling through TLR4, NFκB, and MAP kinase is reduced, and CD4+ T cell activation is inhibited (Yi et al., 2011). Knockout of the SRA/CD204 gene, although decreasing Hsp10 binding to DC led to a profoundly increased ability to stimulate melanoma antigen gp100-specific naïve T cells, compared to wild-type mice (Qian et al., 2011). HSP–SR interactions may thus send both pro-immune and inhibitory signals resulting in a tightly regulated system. Signaling through SRECI appears to reinforce antigen cross presentation and the appearance of SRECI in lipid rafts after binding Hsp90 may be a key stage in this process (Murshid et al., 2010). Lipid rafts are cholesterol- and sphingolipid-rich membrane microdomains that can concentrate molecules involved in cell signaling (Lingwood et al., 2009). Although lacking the glycerophosphoinositide anchor domain motifs found in many raft-associated membrane proteins, SRECI contains other motifs that would permit it to associate with lipid rafts (Murshid et al., 2011a). Indeed, Hsp90–SRECI complexes associate with the small GTPase Cdc42 and non-receptor tyrosine kinase Src, molecules tightly associated with lipid rafts (Murshid et al., 2010). These associations appear to be important in regulating antigen cross presentation of Hsp90-associated antigens in DC.

Lipid rafts also concentrate intermediates in the TLR4 signaling pathway in response to innate immune stimuli (Triantafilou et al., 2002). Indeed, preliminary studies show significant colocalization of Hsp90–SRECI complexes with TLR4 (Murshid, A., and Calderwood, S. K., in preparation). HSP-triggered signaling through SRECI and LOX-1 may thus be involved both in amplifying antigen cross presentation and in stimulating innate immunity and these receptors may operate in concert to thwart the inhibitory effects of HSP–SRA/CD204 signaling. It may be significant that LOX-1, with essentially no sequence similarity to SRECI associates with TLR2 after ligand binding and mediates immune responses in a similar way to SRECI (Jennin et al., 2005). The similarity in immune properties and protein interaction partners between SRECI and LOX-1 despite sequence homology may suggest functional interaction on the cell surface after HSP binding.
CONCLUSION
On theoretical grounds, HSPs might be seen as ideal sources of tumor antigens due to their high abundance in cancer and their molecular chaperone functions. However, the nature of the polypeptides chaperoned by HSPs which carry the “antigenic load” of the HSPPC is less clear. Most cytoplasmic peptides appear to be in free, unchaperoned form unless acquired by TAP, although Hsp90 appears to be an exception to this rule and appears to be capable of binding to peptides exiting the proteasome. However, Hsp70 and Hsp90 both associate with intact proteins in vivo during protein folding and quality control, and the antigenic nature of extracellular HSPs extracted from tumors may thus at least partially reflect stable chaperone binding to antigenic proteins.

It seems clear that HSPs can mediate cross presentation of acquired tumor antigens by APC. This process may involve receptor-mediated uptake by SR LOX-1 or SREC-I or receptor-independent uptake. If small peptides are bound to HSPs they can then be presented to CD8+ cells through the rapid vacuolar pathway of antigen cross presentation. Hsp90 appears to be able to chaperone whole proteins such as ovalbumin across the plasma membrane, into endosomes, and direct them to the proteasome for processing and presentation by MHC class I molecules.

In addition to directing antigens toward the Class I pathway, HSPs can chaperone antigens toward the Class II pathway of antigen presentation. This effect may be significant in recruiting antigen-specific Th1 helper cells to mediate DC licensing and amplify CTL processing.

Association of HSP-antigen complexes with SR SREC-I and LOX-1 may help to amplify cross presentation of antigens by triggering signal transduction pathways emanating from lipid rafts. HSP-bound SR can associate with lipid rafts and activate signaling through small GTPase Cdc42, tyrosine kinase c-sel, and induce activity of PRR such as TLR2. There also appear to be HSP-mediated regulatory signals and binding to SRA/CD204 can inhibit immunity.

There remains a need to identify a number of unresolved cell biological and biochemical aspects of HSPPC-mediated immunity. These include further investigation of the signals initiated when HSPs bind to cell surface receptors, the kinetics of compartmentalization of the chaperoned peptides and the routes of trafficking and processing of peptides after release from HSP. Advanced technology studies of the trafficking of single cell molecules may open up this field. Elucidating the mechanisms of antigen cross presentation of HSP-bound antigens via MHC-I and the signaling events associated with this immunogenic effect may allow development of superior HSP-based vaccines and immunotherapy protocols.

ACKNOWLEDGMENTS
This work was supported by NIH research grants RO-1CA047407, RO1CA119045, and RO-1CA094397.

REFERENCES


HSPs in antigen cross presentation


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 09 December 2011; accepted: 14 March 2012; published online: 30 March 2012.


This article was submitted to Frontiers in Antigen Presenting Cell Biology, a specialty of Frontiers in Immunology.

Copyright © 2012 Murshid, Gong and Calderwood. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.